Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases.

Please login or register to bookmark this article
Bookmark this %label%

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.

View the full article @ Journal of nephrology
Get PDF with LibKey

Authors: Julie Boudali, Benjamin Hallak, Marie Haeck, Anne-Laure Sellier-Leclerc, Marc Ulrich, Paul Coppo, Stéphanie Tellier, François Provôt